ALX Oncology (NASDAQ:ALXO) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of ALX Oncology (NASDAQ:ALXO) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $4.00 price target on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and an average price target of $3.50.

ALX Oncology Price Performance

ALXO stock opened at $1.38 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.52 and a current ratio of 2.40. The business has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $0.92. The company has a market capitalization of $74.82 million, a P/E ratio of -0.68 and a beta of 1.23. ALX Oncology has a 52-week low of $0.40 and a 52-week high of $2.27.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Friday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). Research analysts expect that ALX Oncology will post -2.76 EPS for the current fiscal year.

Insider Activity

In other ALX Oncology news, CEO Jason Lettmann bought 71,163 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The stock was purchased at an average cost of $1.08 per share, with a total value of $76,856.04. Following the transaction, the chief executive officer directly owned 305,121 shares in the company, valued at $329,530.68. This trade represents a 30.42% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 21.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. purchased a new stake in ALX Oncology during the first quarter worth about $46,000. Bridgeway Capital Management LLC bought a new position in shares of ALX Oncology during the 3rd quarter valued at approximately $66,000. AQR Capital Management LLC increased its stake in shares of ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after purchasing an additional 77,065 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of ALX Oncology in the 2nd quarter worth approximately $84,000. Finally, Nuveen LLC bought a new stake in shares of ALX Oncology in the 1st quarter worth approximately $103,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.